LLY Today - Aug 07: Eli Lilly's GLP-1 Sales Boost

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

LLY Today - Aug 07: Eli Lilly's GLP-1 Sales Boost

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey, your friendly neighborhood investor. I’ve been around the block a few times, and today I’m breaking down Eli Lilly, or LLY, for August 7th. Spoiler alert: it was a green day, just barely, up 0.05%.

So, what went down? Honestly, not a ton of movement. The stock barely budged, but it’s still hanging in there. Volume was steady, which is kind of a good sign that folks are still interested, even if the price didn’t jump through the roof.

Now, here’s the juicy part on why it moved a bit. Eli Lilly is riding high on the success of their GLP-1 drugs, which are doing really well. There’s some chatter about how they’re pulling ahead of Novo Nordisk in this space, and that’s got investors feeling a little more optimistic. Plus, Truist just raised their price target, which adds a nice sprinkle of confidence in the mix. People are starting to see Eli Lilly as a solid player in the pharma game, especially with all the buzz around their incretin drugs.

And there’s something to keep in mind going forward—earnings reports are coming up. That could shake things up a bit, so keep an ear to the ground on that front.

So, that’s the scoop on Eli Lilly today! Just a tiny bump in the road, but hey, every little bit counts, right? Remember, this is just a rundown and not financial advice. Catch you later!

まだレビューはありません